The Wolverine Stack: BPC-157 + TB-500 — What the Evidence Actually Shows

The short version

The Wolverine Stack combines BPC-157 (a gastric peptide) and TB-500 (synthetic thymosin beta-4) for accelerated tissue healing. It’s the most popular peptide combination in biohacking.
No study has ever tested the combination. The entire stack is based on theoretical complementarity — not demonstrated synergy.
BPC-157 has 3 published human studies totaling ~30 subjects. Zero randomized controlled trials. Zero efficacy data in humans. Its popularity is built almost entirely on animal research.
TB-500 has significantly more human data: two Phase I safety trials (94 total subjects), Phase II wound healing trials, a Phase III eye drop trial, and a pilot cardiac study — but no approved indications.
Both peptides promote angiogenesis (new blood vessel formation). This is why they heal tissue — and why there’s a legitimate theoretical concern about tumor growth in people with existing cancers.
BPC-157’s entire research program has a conflict-of-interest problem: 83% of all publications come from one researcher who owns the company that ran the (unpublished) clinical trial.
Both were placed on the FDA’s Category 2 restricted list in 2023. RFK Jr. announced in February 2026 they would return to Category 1, but no formal rule has been published yet. Both are banned by WADA.

Why everyone’s talking about this stack

If you’ve torn a tendon, strained a ligament, had surgery, or just have the kind of chronic joint pain that won’t quit — you’ve probably encountered the Wolverine Stack.

Named after the Marvel character whose defining superpower is near-instant regenerative healing, the stack combines two peptides: BPC-157 and TB-500. The promise is straightforward: heal faster, recover better, get back to training sooner.

The appeal is obvious. The evidence picture is more complicated than almost anyone telling you about this stack is willing to admit.

Here’s what we’re going to do in this article: lay out exactly what each peptide is, what the research actually shows (and doesn’t show), why people combine them, what the real risks are, and what you should know before deciding whether this is something you want to pursue.

BPC-157: The gastric peptide with a credibility problem

What it is

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a protein naturally found in human gastric juice. It was discovered and has been almost exclusively studied by Predrag Sikiric and his research group at the University of Zagreb, Croatia.

The “body protection compound” name comes from its apparent ability to protect and repair multiple organ systems — gut, tendons, muscles, bones, nerves, and more. In animal studies, the breadth of effects is remarkable.

The evidence-popularity gap

Here’s the uncomfortable truth that defines BPC-157:

It is the single most popular peptide in the biohacking community. It anchors the Wolverine Stack. It’s discussed constantly on Reddit, podcasts, and at every peptide clinic in the country. Thousands of people inject it regularly.

It has essentially zero human efficacy data.

Let that sink in. The most widely used peptide in biohacking has:

212 PubMed-indexed publications — but 175 of them (83%) are authored by Sikiric’s group
3 published human studies totaling approximately 30 subjects — all by the same author (Edwin Lee), all in the same low-tier journal, none with control groups or blinding
Zero randomized controlled trials in humans
Zero published human efficacy data
A missing Phase I trial (NCT02637284): 42 volunteers were enrolled in 2015 by PharmaCotherapia — a company Sikiric owns. Results were withdrawn from ClinicalTrials.gov in 2016 with no explanation. This would have been the foundational human pharmacokinetic study. It simply vanished.

The 2025 pilot study confirmed that IV BPC-157 at 10-20 mg is safe in 2 humans. That’s it. That’s the entire human evidence base.

The conflict-of-interest problem

This isn’t a minor issue. Sikiric holds patents on BPC-157 (since 1989), owns PharmaCotherapia (the company that ran and then withdrew the Phase I trial), and is CEO of Diagen (the patent holder that has advertised BPC-157 rights for sale). None of these conflicts are disclosed in his 175 publications.

This has been flagged by investigative journalists at Undark and STAT News, and by independent researchers. It doesn’t mean the animal data is fabricated — but it means no independent research group has replicated the core findings. In science, replication is how you build confidence. It hasn’t happened here.

What the animal data does show

Setting aside the credibility concerns, the preclinical evidence is genuinely impressive:

Tendon healing: Accelerated recovery of transected Achilles tendons, with improved biomechanical properties (tensile strength, load to failure)
Gut protection: Reduces gastric lesions, heals inflammatory bowel damage, protects against NSAID-induced gut injury
Bone healing: Accelerated fracture repair with improved bone density markers
Nerve regeneration: Promoted peripheral nerve recovery after transection
Spinal cord injury: Functional improvement after spinal cord compression in rats
Brain injury: Reduced lesion volume after traumatic brain injury
Organ protection: Protective effects demonstrated in liver, kidney, and heart models

The mechanism involves VEGFR2 activation (triggering angiogenesis), FAK-paxillin signaling, and nitric oxide system modulation. BPC-157 essentially tells your body to build new blood vessels and accelerate the entire tissue repair cascade.

The cancer question

And this is exactly why there’s a concern.

Angiogenesis — the formation of new blood vessels — is how healing works. It’s also how tumors grow. Cancers need blood supply. They hijack the angiogenesis machinery to feed themselves.

BPC-157 is a potent angiogenic agent. Sikiric has claimed anti-tumor potential, citing a single unreplicated 2004 in vitro melanoma study. Independent researchers have noted he has zero in vivo solid tumor data addressing this concern.

The honest answer: We don’t know if BPC-157 promotes tumor growth in humans. No study has tested this. The theoretical concern is legitimate based on the mechanism. If you have known or suspected cancer, this is a real risk to discuss with an oncologist.

TB-500: The better-studied half of the stack

What it is

TB-500 is a synthetic version of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide naturally produced by the thymus gland and found in virtually every human cell. Tβ4 was discovered by Allan Goldstein at the NIH in the 1960s and has been studied for over 50 years.

A critical clarification: “TB-500” as sold by research vendors is usually full-length Thymosin Beta-4, not the 7-amino-acid fragment (Ac-LKKTETQ) that the name technically refers to. What you buy depends on the vendor. The clinical trials used full-length Tβ4.

The human evidence — substantially more than BPC-157

TB-500/Tβ4 has a real clinical development program behind it, run by RegeneRx Biopharmaceuticals (founded by Goldstein in 1982):

Phase I Safety (94 total subjects across 2 trials):

US trial (Ruff et al., 2010, PMID: 20536472): 40 healthy volunteers received IV doses up to 1,260 mg daily for 14 days. No dose-limiting toxicities. No serious adverse events.
Chinese trial (Wang et al., 2021, PMID: 34346165): 54 SAD + 30 MAD subjects. Linear pharmacokinetics. Half-life of 0.5-2 hours IV. No serious adverse events. Anti-drug antibodies minimal and transient.

Phase II Wound Healing:

Venous stasis ulcers (73 patients, double-blind, 10 European centers): ~25% complete healing within 3 months [PMID: 17495250]
Pressure ulcers (143 patients): Accelerated healing by nearly a month in patients that healed [PMID: 23050815]

Phase II/III Eye Drops (RGN-259):

Phase II dry eye (72 patients, double-masked): Significant improvements in corneal staining and ocular discomfort [PMID: 26056426]
Phase III neurotrophic keratopathy (18 completed): 60% complete corneal healing vs 12.5% placebo — narrowly missed statistical significance due to early termination from slow enrollment [PMID: 36613994]
Three Phase III ARISE dry eye trials (1,600+ patients): Failed to meet pre-specified primary endpoints

Cardiac pilot (STEMI):

10 patients: Tβ4-pretreated progenitor cell transplantation improved left ventricular ejection fraction >50% (p<0.05) and 6-minute walk distance by 75.7m vs 38.2m in control [PMID: 27288307]

Two landmark Nature papers:

Bock-Marquette et al. (2004): Tβ4 activates cardiac cell survival via ILK/Akt pathway [PMID: 15565145]
Smart et al. (2007): Tβ4 mobilizes adult epicardial progenitor cells for heart regeneration [PMID: 17108969]

How TB-500 works

TB-500’s primary intracellular function is actin sequestration — it binds to monomeric actin and maintains a reservoir of building blocks that cells can rapidly deploy when they need to migrate, divide, or change shape. This is the molecular basis for its wound-healing effects.

Beyond actin, TB-500:

Promotes cell migration to injury sites
Drives angiogenesis via VEGF upregulation (2.5-3.8 fold)
Suppresses inflammation through NF-κB inhibition
Reduces fibrosis (scarring) via TGF-β/Smad modulation
Mobilizes and differentiates stem/progenitor cells
Contains an N-terminal fragment (Ac-SDKP) with independent anti-inflammatory and antifibrotic activity

The horse racing connection

Before TB-500 was a biohacking compound, it was a horse racing drug.

In the early-to-mid 2000s, TB-500 was widely used in competitive horse racing for its recovery and performance benefits. This led to major regulatory action:

The Racing Medication and Testing Consortium classified TB-500 as a Class 1 substance (highest violation level) with Class A penalties (most severe)
In March 2020, the U.S. Department of Justice announced the largest prosecution of racehorse doping in history: 27 indicted, including 11 trainers and 7 veterinarians. TB-500 was among the substances used. 19 received prison sentences.
The Essendon Football Club scandal (Australian AFL, 2012): 34 players were ultimately found guilty by the Court of Arbitration for Sport and suspended for two years after being administered thymosin beta-4 by a rogue sports scientist.

The equine veterinary market created the initial supply chain for TB-500. As word spread about healing properties observed in horses, the human biohacking community adopted it in the 2010s.

TB-500’s cancer question

The same concern that applies to BPC-157 applies here — possibly more so.

A 2003 study by Cha, Jeong, and Kleinman found that Tβ4 overexpression in a mouse melanoma model produced tumors that were 63% larger and generated 4.3x more metastatic lung nodules with 4.4x more blood vessel formation within tumors [PMID: 14625258].

However, the picture is more nuanced. In multiple myeloma, Tβ4 acts as a tumor suppressor — overexpression decreased proliferation, increased apoptosis, and extended survival in mice [PMID: 19833631].

The relationship between Tβ4 and cancer is context-dependent. In solid tumors where cell migration drives metastasis (melanoma, colon, lung), it may promote spread. In certain blood cancers, it has the opposite effect. No human clinical trial has shown cancer promotion, but no long-term cancer surveillance has been conducted either.

Why people combine them — the Wolverine Stack rationale

The theoretical case for combining BPC-157 and TB-500 is built on complementary mechanisms:

	BPC-157	TB-500
Origin	Human gastric juice	Thymus gland (ubiquitous in cells)
Primary action	Localized tissue repair	Systemic healing, cell migration
Angiogenesis	VEGFR2 pathway	VEGF + endothelial migration
Inflammation	Moderate (NO system, gut axis)	Strong (NF-κB inhibition)
Stem cells	Limited evidence	Mobilizes and differentiates progenitors
Gut healing	Strong (primary function)	Limited
Fibrosis	Promotes organized collagen	Reduces fibrosis (Ac-SDKP fragment)
Human trials	3 (no controls, ~30 subjects)	Multiple Phase I-III (hundreds of subjects)

The healing cascade has three phases:

Inflammation (Days 1-5): TB-500 suppresses inflammatory cytokines. BPC-157 upregulates growth factors at the injury site.
Proliferation (Days 5-21): BPC-157 drives fibroblast proliferation and collagen synthesis. TB-500 mobilizes stem cells and supports angiogenesis.
Remodeling: Both promote organized tissue architecture through different molecular pathways.

The logic is sound. But to be clear: no study has tested this combination. Not in animals. Not in cells. Not in humans. Every claim about the Wolverine Stack’s synergistic effects is extrapolated from individual mechanism studies. “Complementary mechanisms” is a hypothesis, not evidence.

Regulatory status — where things stand in 2026

FDA: Both BPC-157 and TB-500 were placed on the FDA’s Category 2 bulk drug substance list in September 2023, effectively banning compounding pharmacies from preparing them.

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced on The Joe Rogan Experience that approximately 14 of the 19 restricted peptides would return to Category 1 — including BPC-157 and TB-500. This would restore legal access through compounding pharmacies with a physician’s prescription.

As of April 2026: No formal FDA rule change has been published. The announcement has been made, but the legal status hasn’t officially changed yet.

Critical distinction: Moving from Category 2 to Category 1 is not FDA approval. It means compounding pharmacies can legally prepare the peptide under a physician’s prescription. It does not mean BPC-157 or TB-500 has been proven safe or effective by FDA standards.

WADA: Both are prohibited at all times — BPC-157 since 2022 (Category S0: Non-Approved Substances), TB-500 since 2018 (Category S2: Growth Factors and Growth Factor Modulators). Athletes using either compound risk a suspension.

Australia: Both classified as prescription-only medicines — though effectively unavailable through legitimate channels.

Safety — what we know

TB-500 safety data is reasonably robust:

94 subjects across two Phase I trials with no serious adverse events
IV doses up to 1,260 mg daily for 14 days tolerated without dose-limiting toxicity
Hundreds of additional subjects across Phase II/III trials
Common side effects: injection site reactions, occasional headache/fatigue

BPC-157 safety data is extremely thin:

The 2025 pilot confirmed IV safety in 2 humans
Animal toxicology shows no organ damage at high doses
No formal human pharmacokinetic data (the Phase I trial results were withdrawn)
Common community-reported side effects: injection site pain, occasional nausea, headache

The unresolved risk for both: Angiogenesis-driven tumor growth in people with existing cancers. Neither peptide has been studied in cancer patients or with long-term cancer surveillance.

The honest assessment

What’s real:

Both peptides have well-characterized mechanisms that are relevant to tissue healing
TB-500 has genuine clinical data supporting wound healing, corneal repair, and cardiac protection
BPC-157’s animal data across dozens of tissue types is remarkably consistent
Thousands of people have used the Wolverine Stack and report faster recovery from injuries

What’s not established:

The combination has never been tested — in any model
BPC-157 has no human efficacy data
Neither peptide is approved for any indication
Long-term safety in humans is unknown
The cancer risk is theoretical but scientifically legitimate
Quality control for research-grade peptides is inconsistent

What’s concerning:

BPC-157’s entire research base has a serious conflict-of-interest problem
The disappeared Phase I trial raises questions that have never been answered
The gap between what’s claimed and what’s proven is wider for BPC-157 than perhaps any other compound in the biohacking space

If you’re going to try it anyway

We’re an educational resource, not your doctor. But if you’ve weighed the evidence and decided to proceed:

Get a physician involved. This is especially important given the FDA reclassification — once Category 1 status is formalized, compounding pharmacies with physician oversight will be the legitimate access route.
Source matters. Pharmaceutical-grade compounded product under a prescription is fundamentally different from reconstituted research-grade peptide ordered online. Quality testing has found significant purity and potency issues with gray-market vendors.
The common protocol: BPC-157 at 250-500 mcg/day subcutaneous + TB-500 at 2-2.5 mg twice weekly, for 4-6 week loading cycles. This is what the community uses — not what clinical trials validated (because no clinical trial tested this).
If you have any history of cancer, discuss the angiogenesis concern with your oncologist before using either peptide.
Monitor and document. Track your symptoms, recovery metrics, and any side effects. Your n=1 data contributes to the collective understanding, even if it’s not clinical evidence.

Sources

Sikiric P. et al. Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology, 2018;16(5):446-462. PMID: 28829350
2025 BPC-157 pilot IV safety study in humans (n=2, doses 10-20 mg)
ClinicalTrials.gov NCT02637284 — BPC-157 Phase I, 42 volunteers enrolled 2015, results withdrawn 2016
Ruff D. et al. Phase I thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010;1194:223-229. PMID: 20536472
Wang X. et al. Phase I recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228. PMID: 34346165
Bock-Marquette I. et al. Thymosin beta4 activates ILK and promotes cardiac repair. Nature. 2004;432:466-472. PMID: 15565145
Smart N. et al. Thymosin β4 induces epicardial progenitor mobilization. Nature. 2007;445:177-182. PMID: 17108969
Guarnera G. et al. Thymosin beta-4 and venous ulcers: European RCT. Ann N Y Acad Sci. 2007;1112:407-412. PMID: 17495250
Treadwell T. et al. Thymosin β4 accelerates dermal healing. Ann N Y Acad Sci. 2012;1270:37-44. PMID: 23050815
Sosne G., Ousler G. Thymosin beta 4 for dry eye: Phase II. Clin Ophthalmol. 2015;9:877-884. PMID: 26056426
Sosne G. et al. RGN-259 Phase III for neurotrophic keratopathy. Int J Mol Sci. 2022;24(1):554. PMID: 36613994
Zhu J. et al. Thymosin β4-pretreated EPC transplantation in STEMI. Cytotherapy. 2016;18(8):1037-1042. PMID: 27288307
Xiong Y. et al. Thymosin beta 4 neuroprotection after TBI. J Neurosurg. 2012;116(5):1081-1092. PMID: 22324420
Morris D.C. et al. Thymosin β4 dose response for acute stroke. J Neurol Sci. 2014;345(1-2):61-67. PMID: 25060418
Malinda K.M. et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364-368. PMID: 10469335
Philp D. et al. Thymosin beta4 activates hair follicle stem cells. FASEB J. 2004;18(2):385-387. PMID: 14657002
Grant D.S. et al. Thymosin β4 actin-binding site promotes angiogenesis. FASEB J. 2003;17(14):2103-5. PMID: 14500546
Cha H.J. et al. Thymosin beta4 role in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003;95(22):1674-80. PMID: 14625258
Sribhen K. et al. Thymosin β4 tumor suppressor in multiple myeloma. Haematologica. 2010;95(1):1-5. PMID: 19833631
Spurney C.F. et al. Thymosin β-4 in dystrophin-deficient mice. PLoS One. 2010;5(1):e8976. PMID: 20126456
Goldstein A.L. History of the discovery of the thymosins. Ann N Y Acad Sci. 2007;1112:1-13. PMID: 17600284
Low T.L. et al. Complete amino acid sequence of bovine thymosin beta 4. PNAS. 1981;78(2):1162-1166. PMID: 6940133
Sosne G. et al. Thymosin beta 4 corneal wound healing after alkali injury. Exp Eye Res. 2002;74(2):293-299. PMID: 11950239
Wang W. et al. Thymosin Beta-4 protects against mouse coronavirus. Virol Sin. 2021;36(5):1-11. PMID: 33967626
Kost N.V. et al. Semax and selank inhibit enkephalin-degrading enzymes. Bioorg Khim. 2001;27(3):180-3. PMID: 11443939
2025 Systematic review of BPC-157 in orthopedic sports medicine
WADA Prohibited List 2022 — BPC-157 (S0: Non-Approved Substances)
WADA Prohibited List 2018 — Thymosin Beta-4 (S2: Growth Factors)
US DOJ March 2020 indictment — racehorse doping prosecution (27 indicted, 19 imprisoned)
Essendon Football Club / CAS guilty verdict January 12, 2016 (34 players suspended)